J&J in the Hunt for China M&A

Johnson & Johnson is using “external innovation” in China as a low-cost, highly inventive path to discover new drugs. "We have to seek the best science and technology,” said Lily Lee, PhD, vice-president and head of JNJ Pharmaceutical R&D Asia, at a recent Shanghai biopharma meeting. "We are especially interested in oncology, infectious diseases and metabolic areas, so M&As in these areas will be high on our radar screen," she continued. More details.... Stock Symbol: (NYSE: JNJ)